IDEXX Laboratories (NASDAQ:IDXX) Issues FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 14.450-14.900 for the period, compared to the consensus EPS estimate of 14.520. The company issued revenue guidance of $4.7 billion-$4.8 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Trading Up 2.4%

IDEXX Laboratories stock traded up $13.52 during mid-day trading on Wednesday, hitting $576.49. The stock had a trading volume of 164,531 shares, compared to its average volume of 522,834. The stock has a 50-day simple moving average of $588.09 and a two-hundred day simple moving average of $650.80. The stock has a market capitalization of $45.79 billion, a PE ratio of 44.20, a P/E/G ratio of 3.42 and a beta of 1.58. IDEXX Laboratories has a 12 month low of $471.74 and a 12 month high of $769.98. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the business earned $2.91 earnings per share. The company’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories will post 14.54 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on IDXX shares. Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. UBS Group reduced their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. BTIG Research cut their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

Insider Buying and Selling

In other news, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the sale, the chief executive officer owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.79% of the stock is currently owned by company insiders.

Trending Headlines about IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q1 results beat expectations: IDEXX reported $3.47 EPS vs. consensus ~$3.41 and revenue of $1.141B (up ~14% y/y). Results showed organic growth in Companion Animal Group and margin improvement, supporting near‑term earnings momentum. IDEXX Laboratories Announces First Quarter Results
• Positive Sentiment: Company raised FY‑2026 EPS guidance to $14.450–$14.900 (consensus ~14.52), signaling management confidence in diagnostics growth and innovation — a bullish catalyst for forward earnings expectations. IDEXX Laboratories Lifts Guidance on Robust Q1
• Neutral Sentiment: Earnings-call materials and transcript provide color on drivers (diagnostics cadence, CAG strength, product cadence) for analysts and investors to model forward growth; see the slides and full call transcript for management commentary. IDEXX Laboratories, Inc. 2026 Q1 – Results – Earnings Call Presentation IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Several analyst/news writeups highlight the beat, margin expansion and guidance lift — useful for gauging consensus revisions and sentiment changes that may drive near‑term analyst actions. IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, ’26 View Up
• Negative Sentiment: Valuation concern: commentary and articles question whether IDXX’s recent ~18% one‑year rally leaves less upside, prompting some investors to reassess risk/reward despite the beat and guidance. That valuation debate may pressure the stock even after strong fundamentals. Is It Too Late To Consider IDEXX Laboratories (IDXX) After Its 18.5% One-Year Rally?

Hedge Funds Weigh In On IDEXX Laboratories

Several hedge funds have recently made changes to their positions in the stock. Compound Planning Inc. boosted its stake in IDEXX Laboratories by 51.9% during the fourth quarter. Compound Planning Inc. now owns 1,802 shares of the company’s stock valued at $1,219,000 after buying an additional 616 shares during the period. Invesco Ltd. grew its holdings in shares of IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after acquiring an additional 181,955 shares during the period. Axxcess Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 37.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 1,707 shares of the company’s stock worth $1,155,000 after purchasing an additional 465 shares in the last quarter. Birchwood Financial Partners Inc. bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $82,000. Finally, Corient Private Wealth LLC boosted its position in shares of IDEXX Laboratories by 58.9% in the 4th quarter. Corient Private Wealth LLC now owns 184,587 shares of the company’s stock worth $124,879,000 after purchasing an additional 68,410 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.